Coloplast A/S (0QBO) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Coloplast A/S DKK 205, price DKK 414, upside -50.5%, quality 76 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range kr 373.75 – kr 1,033 · fair‑value band kr 140.39 – kr 283.44 · the kr 414.15 price screens above the kr 205.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments.
Show more
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Stock analysis
Coloplast A/S (0QBO) currently trades at kr 414.15, while our model-based Fair Value estimate is kr 205.18, 50.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 196.17 per share, and 0 of the 25 models we run sit above the kr 414.15 price.
Bear case: the Earnings-Based group reads lowest at kr 53.91, and 25 of the 25 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 140.39 (bear) to kr 283.44 (bull), the price of kr 414.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Coloplast A/S reported revenue of 19.4B DKK in FY2021 versus 15.5B DKK in FY2017, a compound +5.8%/yr. Reported net income was 4.8B DKK in FY2021, compounding +6.2%/yr from FY2017.
Key figures
Market cap 190B DKK (≈ $28.6B) · P/S ratio 6.78 · Dividend yield 5.6% · Net margin 24.8% · Return on equity 14.1% · Return on assets (EBIT) 41.5% · Operating margin 25.7% · Revenue (TTM) 28.0B DKK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −50%, 0QBO screens richer than that median.
Fair Value models
Bear kr 140.39Fair Value kr 205.18Bull kr 283.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.4% (2017) → 31.7% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Coloplast A/S Fair Value". https://www.fairvalue-calculator.com/stock/0QBO
Frequently asked questions
Is Coloplast A/S (0QBO) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of kr 205.18 versus a price of kr 414.15, about −50% upside (overvalued).
What is the fair value of 0QBO?
Our model-based fair value for Coloplast A/S is kr 205.18 (as of Sep 29, 2026), built from audited fundamentals. The current price: kr 414.15.
What is the quality score of 0QBO?
Coloplast A/S has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Coloplast A/S (0QBO)?
Our model-based price target is the fair value of kr 205.18 (as of Sep 29, 2026) from 25 valuation models. Cautious scenario kr 140.39, optimistic scenario kr 283.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Coloplast A/S stock forecast for 2026?
Our models put fair value at kr 205.18, about −50% upside versus a price of kr 414.15 (overvalued). Cautious scenario kr 140.39, optimistic scenario kr 283.44. The calculation is refreshed regularly with new filings.
What is the revenue of Coloplast A/S (0QBO)?
Coloplast A/S reported trailing-twelve-month revenue of about 28.0B DKK (latest available figure, as of Sep 29, 2026).
Does Coloplast A/S pay a dividend?
Coloplast A/S currently shows a dividend yield of about 5.55% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of Coloplast A/S (0QBO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Coloplast A/S it is kr 205.18 per share (as of Sep 29, 2026), against a price of kr 414.15. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Coloplast A/S stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0QBO trades above its calculated fair value: price kr 414.15, fair value kr 205.18, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QBO?
No. The price is what the market pays today (kr 414.15); the fair value is what the company's own numbers justify (kr 205.18). For Coloplast A/S the two are kr 208.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Coloplast A/S worth?
The market values Coloplast A/S at about 190B DKK (market capitalisation, as of Sep 29, 2026). Per share that is kr 414.15; our models calculate a fair value of kr 205.18 per share.
What do the bullish and bearish scenarios say about 0QBO?
Our models span a range for Coloplast A/S: cautious scenario kr 140.39, base kr 205.18, optimistic kr 283.44 per share (as of Sep 29, 2026, price kr 414.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0QBO from its 52-week high?
Coloplast A/S trades at kr 414.15, about 31% below its 52-week high of kr 597.56 and 11% above the low of kr 373.75 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 205.18 is for.
Which stocks are comparable to Coloplast A/S?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Coloplast A/S stock attractive at the current price?
The data as of Sep 29, 2026: price kr 414.15, calculated fair value kr 205.18 (−50%), Quality Score 76/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QBO calculated?
We run Coloplast A/S through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 205.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Coloplast A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Coloplast A/S (0QBO)?
The closing price on Oct 2, 2026 was kr 414.15. Our model-based fair value is kr 205.18, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Coloplast A/S right now?
A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (kr 283.44). The favourable scenario is already priced in. A fairly wide model range (kr 140.39 to kr 283.44) leaves room in how you read the outcome.
Key figures of Coloplast A/S
How large is the market capitalisation of Coloplast A/S (0QBO)?
The market capitalisation of Coloplast A/S is 190B DKK (≈ $28.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Coloplast A/S (0QBO)?
The price-to-sales ratio of Coloplast A/S is 6.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Coloplast A/S (0QBO)?
The dividend yield of Coloplast A/S is 5.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Coloplast A/S (0QBO)?
The net margin of Coloplast A/S is 24.8% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Coloplast A/S (0QBO)?
The return on equity (ROE) of Coloplast A/S is 14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Coloplast A/S (0QBO)?
On an EBIT basis the return on assets of Coloplast A/S is 41.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Coloplast A/S (0QBO)?
The operating margin of Coloplast A/S is 25.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Coloplast A/S (0QBO)?
Revenue at Coloplast A/S is growing +2.2% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Coloplast A/S (0QBO)?
Earnings per share at Coloplast A/S are growing +33.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
